Redian新闻
>
求一个Dishnetwork的refer code
avatar
求一个Dishnetwork的refer code# Living
c*m
1
有没有设么特别的原因?
avatar
b*y
2
如题。请回复邮箱。
谢谢!
avatar
c*m
3
这是原因-:
by seeking alpha Nov 21,2010
Bristol-Myers Squibb (BMY) and Pfizer (PFE) said they have discontinued the
late-stage clinical trial of their experimental antiplatelet drug apixaban
in patients with recent Acute Coronary Syndrome on the recommendation of an
independent data monitoring committee because of bleeding among patients
randomized to apixaban. This increase in bleeding was not offset by
clinically meaningful reductions in ischemic events. Enrollment will be
stopped and patients will be taken off of the study drug. The lead
investigators will complete a full evaluation of the available data set and
the results will be made public. The companies are moving forward with
apixaban in other indications. “Our recommendation to discontinue [the
study] concerns only the population of high-risk ACS patients receiving anti
-platelet therapy enrolled in [the study],” said Robert Harrington, Duke
Clinical Research Institute, and co-chair of the study steering committee.
相关阅读
logo
联系我们隐私协议©2024 redian.news
Redian新闻
Redian.news刊载任何文章,不代表同意其说法或描述,仅为提供更多信息,也不构成任何建议。文章信息的合法性及真实性由其作者负责,与Redian.news及其运营公司无关。欢迎投稿,如发现稿件侵权,或作者不愿在本网发表文章,请版权拥有者通知本网处理。